Citi: China Pharma and Biotech ESMO Data Further Validated; Favors CSPC PHARMA , HENGRUI PHARMA , INNOVENT BIO and SKB BIO

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Citi published a research report stating that ESMO 2026 marked another important step forward for China's pharmaceutical and biotechnology sectors. China-developed original assets delivered compelling data across multiple key global studies, demonstrating strong China-to-global consistency, highly watched clinical results, and innovation beyond established targets. The bank believes this helps reduce sector risk, strengthens confidence in global regulatory pathways, overseas commercialization, and the sustainability of cross-border partnerships, and could support structural re-rating for companies with differentiated and internationally competitive pipelines.

The bank noted that several closely watched readouts exceeded investor expectations, including the 15.0-month median progression-free survival in OptiTROP-Lung06, as well as statistically significant progression-free survival and overall survival benefits achieved in HARMONi-GI1. The industry is also seeing a growing number of positive results from randomized and registrational studies, rather than relying mainly on early-stage single-arm data. Improved quality and maturity of clinical evidence should help enhance asset visibility and shift investor focus toward regulatory execution, launch readiness, and commercialization.

The bank added that it remains positive on companies with globally validated assets, sufficiently differentiated pipelines, and clear catalysts. Its top picks in the pharmaceutical sector are CSPC PHARMA (01093.HK) +0.030 (+0.381%) Short selling $228.34M; Ratio 35.067% and HENGRUI PHARMA (01276.HK) -0.350 (-0.690%) Short selling $52.27M; Ratio 26.372% , while its preferred biopharmaceutical names are INNOVENT BIO (01801.HK) +0.900 (+1.129%) Short selling $365.33M; Ratio 35.401% and SKB BIO (06990.HK) +0.600 (+0.141%) Short selling $25.93M; Ratio 8.174% . It is also positive on HUTCHMED (00013.HK) -0.060 (-0.289%) Short selling $6.96M; Ratio 11.914% . (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-02 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.